Stanford Scientists Develop Universal Nasal Spray Vaccine Against COVID-19, Flu, and Pneumonia
A new nasal spray vaccine developed by scientists at Stanford Medicine shows promising results in protecting against a range of respiratory illnesses, including COVID-19, influenza, and bacterial pneumonia, as well as common allergens. The research, published in Science on February 19, 2026, represents a significant step toward creating a universal vaccine capable of providing broad protection against infectious threats. Source
How the Universal Vaccine Works
Unlike traditional vaccines that target specific viruses or bacteria, this experimental vaccine works by supercharging the lungs’ own immune defenses, keeping them on high alert for months. The vaccine enhances the innate immune system, triggering a more aggressive response to pathogens while maintaining a relatively short duration of effect. This stimulation is key to its effectiveness. Source
Promising Results in Mouse Studies
In studies conducted on mice, the nasal spray vaccine provided “broad and long-lasting” protection for three months against Staphylococcus aureus, a common cause of infections, and SARS-CoV-2 (the virus that causes COVID-19). Vaccinated mice exhibited rapid T cell responses and the development of pathogen-specific antibodies, as well as the formation of ectopic lymphoid structures within the lungs. Source
A Double Layer of Protection
The vaccine creates a dual protective barrier. First, a mucosal layer acts as an initial filter. According to Bali Pulendran, PhD, a senior author of the study and an immunologist at Stanford University, the mucosal vaccination activates the pulmonary immune system, enabling a rapid and specific immune response against viruses and effectively expelling those that evade the initial barrier. Source
Potential Impact on Vaccination Campaigns
If proven effective in humans, this universal vaccine could significantly reduce the need for frequent vaccinations, potentially altering current vaccination campaigns for illnesses like the flu and COVID-19. Source
Further Research Needed
The success of this project hinges on the results of human trials. Further research is necessary to determine the vaccine’s efficacy and safety in humans. Source